intended for the treatment of IBD, as well six other inflammatory conditions across rheumatology and dermatology. “We are in a time where biosimilars for Crohn’s disease and ulcerative colitis ...

red down pointing triangle stock moved higher following positive results from the latest trial of their jointly developed treatment for inflammatory bowel disease. The pharmaceutical companies ...

JERUSALEM (Reuters) - Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and Crohn's disease showed it had met primary goals.

Teva Pharmaceuticals' shares soared and Sanofi's stock moved higher following positive results from the latest trial of their jointly developed treatment for inflammatory bowel disease.